Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abraxane + gemcitabine as first-line therapy in cisplatin-ineligible cholangiocarcinoma
2014-004981-52Phase 2Completed
- Sponsor
- Universitätsmedizin Essen
- Start
- Dec 2015
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nab-paclitaxel and gemcitabine in cholangiocarcinoma (CCA), gallbladder cancer and intrahepatic cholangiocarcinoma (ICC), sponsored by Universitätsmedizin Essen. Primary endpoint: overall response rate. Started Dec 2015; status: completed.
02
Drugs
nab-paclitaxelgemcitabine
03
Conditions
cholangiocarcinoma (CCA)gallbladder cancerintrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on 2014-004981-52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004981-52.